elsevi
inc
right
reserv
cough
andor
sputum
product
may
may
present
stage
mild
copd
fev
least
predict
valu
stage
ii
moder
copd
fev
less
predict
valu
stage
iii
sever
copd
defin
fev
predict
valu
presenc
respiratori
failur
rightsid
heart
failur
acut
exacerb
chronic
bronchiti
associ
worsen
dyspnea
elev
sputum
product
increas
sputum
purul
classifi
sever
type
three
symptom
present
moder
type
two
three
present
mild
exacerb
diagnos
one
symptom
occur
along
least
one
follow
upper
respiratori
tract
infect
past
day
fever
without
appar
caus
increas
wheez
increas
cough
respiratori
rate
heart
rate
elev
least
baselin
bronchiti
bronchiti
character
bronchial
inflamm
result
cough
sputum
product
inflamm
acut
natur
usual
result
viral
infect
may
longstand
manifest
chronic
obstruct
pulmonari
diseas
acut
infecti
bronchiti
differ
chronic
bronchiti
respect
etiolog
pathophysiolog
treatment
acut
bronchiti
among
frequent
reason
visit
physician
offic
defin
infecti
gener
viral
respiratori
ill
last
week
occur
otherwis
healthi
adult
cough
predomin
featur
gonzal
sand
addit
cough
usual
sputum
product
acut
bronchiti
frequent
involv
upper
respiratori
symptom
constitut
complaint
fatigu
bodi
ach
ill
compris
symptom
may
classifi
acut
bronchiti
diagnosi
pneumonia
exclud
form
chronic
obstruct
pulmonari
diseas
copd
chronic
bronchiti
character
irrevers
incomplet
revers
airway
obstruct
produc
decreas
maxim
expiratori
airflow
chitkara
sarina
definit
chronic
bronchiti
symptomat
condit
result
mucusproduc
cough
present
least
month
year
consecut
year
underli
etiolog
tuberculosiswisniewski
depend
sever
chronic
bronchiti
may
produc
minim
signific
function
impair
acut
bronchiti
form
lower
respiratori
tract
infect
gonzal
sand
although
etiolog
formal
identifi
small
percentag
clinic
case
ident
diseaseproduc
organ
may
use
classifi
acut
bronchiti
chronic
bronchiti
common
form
chronic
obstruct
pulmonari
diseas
copd
group
condit
involv
airway
obstruct
decreas
maxim
expiratori
airflow
breathingrel
symptom
emphysema
destruct
alveoli
major
manifest
copd
chitkara
sarina
nonremitt
asthma
involv
bronchoconstrict
irrevers
partial
revers
may
also
classifi
cop
unusu
individu
experi
combin
form
copd
involv
sputum
product
alveolar
destruct
bronchospasm
copd
classifi
basi
sever
pauwel
et
al
stage
risk
character
normal
spirometr
read
presenc
chronic
cough
andor
sputum
product
stage
ii
iii
copd
present
forc
expiratori
volum
second
divid
forc
vital
capac
fev
fvc
less
chronic
acut
chronic
bronchiti
give
rise
persist
sputumproduc
cough
bronchial
hyperrespons
wheez
difficulti
breath
dyspnea
may
occur
difficulti
breath
upon
exercis
exert
dyspnea
fairli
common
case
acut
bronchiti
symptom
cough
sputum
product
last
week
gonzal
sand
infect
otiti
media
sinus
rare
pneumonia
may
result
either
primari
viral
infect
secondari
bacteri
infect
acut
bronchiti
result
influenza
may
addit
produc
rare
complic
muscular
inflamm
myositi
muscl
cell
lysi
lead
potenti
fatal
renal
damag
rhabdomyolyisi
addit
consequ
acut
bronchiti
seen
children
rey
syndrom
may
occur
children
influenza
particularli
treat
aspirin
viral
lower
respiratori
infect
earli
life
associ
later
develop
asthma
gern
contrast
acut
bronchiti
resolv
follow
termin
caus
infect
chronic
bronchiti
gener
worsen
time
even
optim
treatment
chitkara
sarina
cessat
exposur
trigger
stimulu
tobacco
smoke
current
avail
therapeut
manag
slow
progress
chronic
bronchiti
usual
time
treatment
sought
irrevers
damag
lung
progress
chronic
bronchiti
lead
short
breath
initi
manifest
exercis
also
occur
rest
diseas
worsen
increas
pulmonari
dysfunct
result
pulmonari
hypertens
right
ventricular
enlarg
rightsid
heart
failur
cor
pulmonal
sign
cor
pulmonal
includ
peripher
edema
enlarg
liver
intern
organ
increas
breath
difficulti
weight
loss
may
occur
muscl
wast
contribut
develop
exercis
intoler
individu
affect
chronic
bronchiti
suscept
repeat
episod
symptom
cough
sputum
product
dyspnea
worsen
mccrori
et
al
episod
term
acut
exacerb
chronic
bronchiti
may
result
viral
rare
bacteri
infect
environment
exposur
tobacco
smoke
air
pollut
allergen
may
also
produc
acut
exacerb
chronic
bronchiti
caus
approxim
onethird
acut
exacerb
unknown
immunocompromis
individu
person
comorbid
condit
diabet
cardiovascular
diseas
pulmonari
diseas
alcohol
gonzal
sand
individu
also
higher
risk
develop
complic
acut
bronchiti
pneumonia
chronic
bronchiti
common
form
chronic
obstruct
lung
diseas
copd
emphysema
alveolar
destruct
next
frequent
observ
manifest
nonremitt
asthma
may
also
classifi
cop
common
individu
copd
exhibit
characterist
chronic
bronchiti
emphysema
bronchospast
diseas
individu
copd
suscept
lower
respiratori
infect
acut
bronchiti
pneumonia
ward
casaburi
chitkara
sarina
advanc
diseas
may
develop
pulmonari
hypertens
result
right
ventricular
enlarg
diseas
progress
rightsid
heart
failur
cor
pulmonal
acut
bronchiti
usual
caus
virus
associ
lower
respiratori
tract
infect
includ
influenza
b
parainfluenza
respiratori
syncyti
viru
human
metapneumoviru
upper
respiratori
tract
infect
rhinoviru
corona
viru
adenoviru
bandi
et
al
common
caus
acut
bronchiti
influenza
much
smaller
percentag
acut
bronchiti
case
result
bacteri
infect
chlamydia
pneumonia
respons
sever
recent
outbreak
particularli
young
adult
bordetella
pertussi
may
caus
atyp
symptom
result
prolong
case
acut
bronchiti
previous
immun
adult
mycoplasma
pneumonia
addit
establish
etiolog
agent
acut
bronchiti
littl
evid
acut
bronchiti
may
caus
bacteri
speci
characterist
pneumonia
infect
eg
streptococcu
pneumonia
chronic
bronchiti
frequent
develop
tobacco
smoker
approxim
eventu
show
symptom
disord
viegi
passiv
exposur
smoke
also
contribut
develop
chronic
bronchiti
caus
factor
includ
exposur
indoor
outdoor
air
pollut
occup
dust
eg
grain
coal
chemic
irrit
eg
sulfur
dioxid
chronic
bronchiti
may
also
develop
peopl
histori
recurr
lung
infect
airway
hyperrespons
hogg
acut
exacerb
chronic
bronchiti
commonli
associ
influenza
parainfluenza
coronaviru
rhinoviru
infect
mccrori
et
al
elev
level
particul
air
pollut
ozon
also
associ
acut
exacerb
role
bacteri
infect
acut
exacerb
chronic
bronchiti
remain
controversi
pathogen
bacteri
haemophilu
influenza
streptococcu
pneumonia
moraxella
catarrhali
present
sputum
approxim
half
experienc
acut
exacerb
also
frequent
present
period
stabl
diseas
hirschmann
clinic
trial
shown
antibiot
therapi
help
less
acut
exacerb
howev
subset
exacerb
purul
sputum
predomin
featur
extent
bacteri
erad
correl
degre
resolut
exacerb
associ
inflamm
white
et
al
thu
increas
bacteri
load
acquisit
new
bacteri
pathogen
chang
antigen
makeup
resid
bacteri
popul
may
respons
certain
acut
exacerb
chronic
bronchiti
role
bacteri
infect
progress
chronic
bronchiti
unclear
wilson
acut
bronchiti
widespread
condit
usual
occur
outbreak
epidem
especi
winter
month
incid
approxim
case
per
person
per
year
file
elev
risk
develop
acut
bronchiti
seen
among
young
elderli
smoker
immunocompromis
individu
person
comorbid
condit
cardiovascular
pulmonari
diseas
alcohol
individu
also
increas
risk
develop
complic
pneumonia
chronic
bronchiti
emphysema
relat
manifest
chronic
obstruct
pulmonari
diseas
copd
often
coexist
individu
accord
nation
health
interview
survey
million
american
diagnos
chronic
bronchiti
million
emphysema
million
barn
et
al
us
copd
primari
caus
death
peopl
year
larg
number
case
may
undiagnos
recent
survey
involv
direct
measur
pulmonari
function
suggest
nearli
million
individu
us
suffer
copd
mannino
et
al
chronic
bronchiti
commonli
seen
individu
age
common
women
men
across
age
group
may
sever
women
barn
et
al
age
group
common
white
black
wherea
revers
true
age
group
signific
risk
factor
develop
chronic
bronchiti
cigarett
smoke
morbid
mortal
increas
proport
extent
durat
smoke
viegi
occup
exposur
dust
eg
coal
grain
cadmium
heavi
metal
industri
chemic
eg
isocyan
certain
adhes
weld
fume
also
pose
signific
risk
develop
chronic
bronchiti
environment
tobacco
smoke
air
pollut
also
associ
increas
risk
develop
copd
histori
childhood
respiratori
infect
correl
increas
risk
copd
hogg
latent
infect
adenoviru
may
enhanc
inflammatori
respons
environment
caus
chronic
bronchiti
may
infect
ulcerogen
bacterium
helicobact
pylorirousso
et
al
colon
lower
airway
haemophilu
influenza
pulmonari
pathogen
may
associ
chronic
bronchiti
acut
exacerb
wilson
bandi
et
al
host
factor
also
involv
develop
cop
low
socioeconom
statu
high
alcohol
consumpt
tendenc
toward
atop
allerg
reaction
hypersensit
associ
copd
viegi
low
dietari
intak
fresh
fruit
veget
antioxid
vitamin
c
betacaroten
fish
fatti
acid
also
associ
impair
lung
function
romieu
trenga
inherit
defici
antitrypsin
proteinas
inhibitor
result
earlyonset
emphysema
viegi
genet
factor
may
also
involv
develop
chronic
bronchiti
gener
sign
symptom
acut
bronchiti
result
pathogen
immun
respons
infect
acut
phase
ill
last
day
involv
constitut
symptom
fever
fatigu
muscl
ach
gonzal
sand
balter
phase
viral
colon
tracheobronchi
epithelium
occur
respons
infect
airway
epitheli
cell
resid
monocyt
macrophag
releas
cytokin
recruit
activ
immun
cell
infect
influenza
viru
provid
exampl
process
influenza
infect
stimul
releas
chemotact
chemokin
includ
rant
monocyt
chemotact
macrophag
inflammatori
proinflammatori
cytokin
tumor
necrosi
factoralpha
tnfalpha
antivir
cytokin
interferonalpha
ifnalpha
ifnbetajulkunen
et
al
neutrophil
among
first
cell
recruit
tracheobronchi
epithelium
increas
number
correl
develop
airway
hyperrespons
lymphocyt
recruit
activ
rant
cytokin
releas
monocyt
eosinophil
recruit
activ
may
persist
week
initi
infect
protract
phase
acut
bronchiti
involv
cough
wheez
sputum
product
last
week
frequent
involv
signific
declin
pulmonari
function
measur
decreas
forc
expiratori
volum
inn
second
fev
bronchial
hyperrespons
initi
acut
phase
persist
sever
week
correl
extend
presenc
activ
inflammatori
cell
patholog
hallmark
chronic
bronchiti
airflow
limit
secondari
inflamm
increas
mucu
product
larg
mm
airway
diseas
process
begin
damag
airway
initi
inflamm
remodel
airway
epithelium
lead
mucu
hypersecret
obstruct
airway
increas
suscept
bacteri
colon
macne
turato
et
al
cosio
piquera
cosio
presenc
pathogen
bacteria
lung
common
caus
acut
exacerb
chronic
bronchiti
may
also
relat
diseas
progress
ongo
cycl
ensu
inflamm
infect
produc
epitheli
damag
perpetu
addit
inflamm
airway
remodel
chronic
bronchiti
initi
repeat
exposur
tobacco
smoke
environment
lung
irrit
eg
coal
grain
dust
air
pollut
andor
respiratori
infect
produc
damag
larg
airway
recruit
inflammatori
cell
result
upregul
adhes
molecul
eselectin
subepitheli
blood
vessel
neutrophil
predomin
cell
type
recruit
lumen
airway
macrophag
lymphocyt
predomin
cell
infiltr
subepitheli
space
eosinophil
preval
subepithelium
acut
exacerb
chronic
bronchiti
larg
number
neutrophil
seen
sever
diseas
enlarg
mucou
gland
formerli
believ
defin
featur
chronic
bronchiti
believ
inflamm
gland
characterist
inflammatori
cell
airway
lumen
epithelium
releas
mediat
control
inflamm
airway
remodel
characterist
chronic
bronchiti
reid
sallenav
neutrophil
releas
reactiv
oxygen
speci
superoxid
peroxynitrit
produc
tissu
damag
inflamm
elev
level
proinflammatori
molecul
ltb
tnfalpha
diminish
level
antiinflammatori
cytokin
seen
sputum
individu
chronic
bronchiti
elev
level
mucusstimul
cytokin
seen
patient
chronic
bronchiti
neutrophil
airway
releas
neutrophil
elastas
serin
proteas
increas
product
mucu
stimul
prolifer
mucusproduc
goblet
cell
squamou
metaplasia
occur
result
replac
mani
ciliat
columnar
epitheli
cell
squamou
epitheli
cell
overal
process
excess
bronchial
mucu
secret
impair
clearanc
result
airway
obstruct
irrit
increas
likelihood
infect
mani
similar
exist
process
occur
larg
small
mm
airway
chronic
bronchiti
subepitheli
infiltr
lymphocyt
goblet
cell
prolifer
contribut
inflamm
mucu
secret
respect
addit
fibrosi
airway
wall
decreas
elast
recoil
lung
hypertrophi
bronchiolar
smooth
muscl
produc
airflow
restrict
attach
alveoli
bronchiol
may
lost
well
pulmonari
arteri
chronic
bronchiti
caus
prolifer
smooth
muscl
cell
deposit
elast
collagen
fiber
turato
et
al
appear
result
endotheli
dysfunct
result
hypoxemia
unknown
factor
pulmonari
hypertens
occur
consequ
pulmonari
arteri
narrow
right
ventricl
may
becom
enlarg
result
prolong
pump
elev
arteri
pressur
right
ventricular
failur
cor
pulmonal
common
complic
chronic
bronchiti
initi
acut
phase
acut
bronchiti
begin
day
constitut
symptom
fever
malais
muscl
ach
gonzal
sand
symptom
variabl
extent
durat
depend
upon
natur
infecti
agent
exampl
rhinoviru
infect
produc
minim
constitut
symptom
wherea
influenza
parainfluenza
produc
sever
prolong
symptom
protract
phase
acut
bronchiti
last
week
involv
cough
increas
sputum
product
wheez
acut
bronchiti
distinguish
upper
respiratori
infect
presenc
cough
sputum
wheez
former
sign
symptom
acut
bronchiti
differ
pneumonia
pneumonia
caus
abnorm
lung
sound
indic
presenc
fluid
eg
rale
elev
vital
sign
heart
rate
beatsminut
respiratori
rate
breathsminut
temperatur
c
pneumonia
confirm
radiographi
unwarr
lowrisk
individu
elev
vital
sign
without
abnorm
lung
sound
particularli
known
viral
outbreak
xray
test
absenc
abnorm
lung
sound
may
necessari
elderli
comorbid
place
high
risk
pneumonia
complic
chronic
bronchiti
manifest
chronic
obstruct
pulmonari
diseas
copd
involv
cough
sputum
product
without
wheez
last
least
month
consecut
year
chitkara
sarina
frequent
appear
smoker
age
associ
acut
exacerb
cough
wheez
sputum
product
increas
person
chronic
bronchiti
increas
risk
develop
pneumonia
respiratori
infect
signific
difficulti
breath
exercis
diseas
progress
also
rest
usual
manifest
midsixti
earli
seventi
spirometr
measur
forc
expiratori
volum
second
fev
forc
vital
capac
fvc
may
use
assess
pulmonari
function
stage
sever
copd
pauwel
et
al
lenfant
khaltaev
complet
blood
count
use
rule
infect
may
reveal
elev
red
blood
cell
result
chronic
hypoxemia
polycythemia
sputum
cultur
may
use
check
acut
infect
chest
xray
perform
exclud
caus
cough
pneumonia
lung
cancer
sever
case
chronic
bronchiti
radiographi
may
reveal
right
ventricular
hypertrophi
well
enlarg
rapid
taper
pulmonari
arteri
emphysema
present
well
region
sever
diseas
visibl
radioluc
area
surround
hairlin
shadow
acut
exacerb
chronic
bronchiti
associ
worsen
dyspnea
increas
sputum
product
purul
acut
exacerb
classifi
sever
type
three
symptom
present
moder
type
two
three
present
mccrori
et
al
mild
exacerb
diagnos
one
symptom
occur
along
least
one
indic
recent
respiratori
infect
eg
fever
cough
wheez
predominantli
viral
natur
acut
bronchiti
best
treat
symptomat
unless
influenza
etiolog
establish
antivir
treatment
initi
earli
enough
ensur
effect
antibiot
use
case
bacteri
infect
confirm
medic
avail
treatment
chronic
bronchitischron
obstruct
pulmonari
diseas
copd
decreas
progress
declin
respiratori
function
characterist
condit
rather
lessen
symptom
complic
intervent
slow
progress
copd
decreas
exposur
substanc
worsen
condit
tobacco
smoke
occup
dust
chemic
air
pollut
smoke
cessat
signific
intervent
potenti
slow
progress
chronic
obstruct
pulmonari
diseas
chitkara
sarina
pharmacolog
therapi
tobacco
depend
ad
counsel
increas
likelihood
success
nicotin
replac
therapi
commonli
given
transderm
patch
nicotin
gum
nasal
spray
inhal
lozeng
use
counteract
breakthrough
crave
smoke
cessat
like
succeed
nicotin
replac
therapi
use
combin
antidepress
bupropion
combin
nicotin
gradual
withdrawn
bupropion
maintain
month
longer
acut
bronchiti
frequent
exhibit
wheez
sign
revers
bronchoconstrict
although
chronic
obstruct
pulmonari
diseas
character
bronchoconstrict
incomplet
revers
follow
administr
bronchodil
longterm
therapi
bronchodil
decreas
symptom
airflow
limit
individu
chronic
bronchiti
thu
bronchodil
therapi
central
manag
chronic
bronchiti
acut
exacerb
chitkara
sarina
inhal
prefer
rout
administr
maxim
deliveri
agent
lung
minim
system
side
effect
shortact
adrenoceptor
agonist
albuterol
produc
rapid
bronchodil
action
adrenoceptor
airway
smooth
muscl
anticholinerg
prefer
drug
treatment
acut
bronchiti
smunci
et
al
treatment
chronic
bronchiti
adrenoceptor
agonist
may
use
schedul
basi
asneed
treat
acut
bronchospasm
adrenoceptor
agonist
also
use
treatment
acut
exacerb
chronic
bronchiti
mccrori
et
al
efficaci
longact
adrenoceptor
agonist
salmeterol
studi
bronchodilatori
effect
anticholinerg
addit
adrenoceptor
agonist
combin
product
deliv
meter
dose
adrenoceptor
agonist
ipratropium
simplifi
drug
administr
acut
bronchiti
frequent
exhibit
wheez
sign
revers
bronchoconstrict
although
chronic
obstruct
pulmonari
diseas
character
bronchoconstrict
incomplet
revers
follow
administr
bronchodil
longterm
therapi
bronchodil
decreas
symptom
airflow
limit
individu
chronic
bronchiti
thu
bronchodil
therapi
central
manag
chronic
bronchiti
acut
exacerb
chitkara
sarina
inhal
prefer
rout
administr
maxim
deliveri
agent
lung
minim
system
side
effect
anticholinerg
bronchodil
ipratropium
block
muscarin
receptormedi
bronchoconstrict
mucu
secret
bronchial
vasodil
result
vagal
stimul
airway
durat
action
ipratropium
longer
shortact
adrenoceptor
agonist
bronchodil
decreas
volum
sputum
produc
without
alter
viscos
ipratropium
inhal
may
use
acut
bronchiti
bronchospasm
problemat
smunci
et
al
chronic
bronchiti
ipratropium
mainstay
therapi
chitkara
sarina
individu
nonrespons
adrenoceptor
agonist
deriv
symptomat
relief
ipratropium
bronchodilatori
effect
ipratropium
addit
adrenoceptor
agonist
combin
product
deliv
meter
dose
adrenoceptor
agonist
ipratropium
simplifi
drug
administr
although
chronic
obstruct
pulmonari
diseas
character
bronchoconstrict
incomplet
revers
follow
administr
bronchodil
longterm
therapi
bronchodil
decreas
symptom
airflow
limit
individu
chronic
bronchiti
thu
bronchodil
therapi
central
manag
chronic
bronchiti
acut
exacerb
chitkara
sarina
theophyllin
exert
wide
varieti
physiolog
action
includ
central
nervou
system
stimul
cardiac
stimul
smooth
muscl
relax
major
action
lung
result
inhibit
cyclic
nucleotid
phosphodiesteras
break
cyclic
amp
cgmp
second
messeng
mediat
bronchodil
theophyllin
also
inhibit
releas
inflammatori
mediat
immun
cell
narrow
therapeut
index
potenti
lifethreaten
side
effect
numer
drug
interact
made
theophyllin
secondlin
therapi
chronic
bronchiti
efficaci
compar
bronchodil
question
subset
patient
appear
benefit
theophyllin
lower
therapeut
dose
use
combin
adrenoceptor
agonist
may
benefici
case
oxygen
oxygen
therapi
indic
symptom
chronic
obstruct
pulmonari
diseas
copd
becom
sever
enough
limit
activ
daili
live
chitkara
sarina
may
also
use
asneed
exercis
nt
qualifi
continu
oxygen
use
oxygen
therapi
reduc
mortal
improv
qualiti
life
person
sever
cop
also
use
manag
acut
exacerb
chronic
bronchiti
mccrori
et
al
antibiot
although
antibiot
frequent
prescrib
acut
bronchiti
case
viral
origin
render
useless
antibiot
therapi
decreas
durat
ill
limit
activ
loss
work
time
case
acut
bronchiti
fahey
et
al
smunci
et
al
bent
et
al
thu
frequenc
antibiot
use
safe
reduc
without
affect
patient
outcom
gonzal
et
al
rare
case
acut
bronchiti
caus
mycoplasma
pneumonia
chlamydia
pneumonia
fluoroquinolon
tetracyclin
macrolid
effect
gonzal
sand
acut
bronchiti
caus
bordetella
pertussi
may
treat
erythromycin
effect
earli
cours
ill
role
bacteri
infect
acut
exacerb
chronic
bronchiti
remain
controversi
exacerb
purul
sputum
predomin
featur
extent
bacteri
erad
correl
degre
resolut
inflamm
associ
exacerb
white
et
al
unit
state
nation
heart
lung
blood
institut
world
health
organ
recommend
antibiot
given
acut
exacerb
evid
infect
eg
increas
sputum
product
chang
sputum
color
andor
fever
pauwel
et
al
commonli
use
antibiot
includ
amoxicillinclavulan
azithromycin
sever
cephalosporin
fluoroquinolon
although
glucocorticoid
frequent
employ
therapi
chronic
bronchiti
use
controversi
chitkara
sarina
glucocorticoid
block
immun
cell
activ
cytokin
releas
mucu
secret
vitro
yet
individu
chronic
obstruct
pulmonari
diseas
actual
respond
imposs
predict
respond
glucocorticoid
inde
benefit
oral
glucocorticoid
acut
exacerb
may
realiz
valu
chronic
inhal
glucocorticoid
use
system
glucocorticoid
eg
prednisolon
use
treatment
acut
exacerb
chronic
bronchiti
allevi
symptom
decreas
hospit
time
reduc
relaps
rate
among
steroidrespons
individu
mccrori
et
al
chronic
treatment
inhal
glucocorticoid
fluticason
produc
modest
reduct
incid
acut
exacerb
impact
rate
function
declin
unit
state
nation
heart
lung
blood
institut
world
health
organ
recommend
longterm
mainten
therapi
inhal
glucocorticoid
symptomat
patient
exhibit
document
spirometr
respons
glucocorticoid
predict
suffer
repeat
exacerb
requir
antibiot
glucocorticoid
therapi
pauwel
et
al
system
glucocorticoid
use
manag
acut
exacerb
chronic
treatment
avoid
due
potenti
sever
advers
effect
influenza
vaccin
significantli
decreas
morbid
mortal
person
chronic
bronchiti
annual
influenza
vaccin
recommend
pauwel
et
al
pneumococc
vaccin
use
patient
chronic
bronchiti
insuffici
data
support
gener
use
purpos
nonsteroid
antiinflammatori
drug
nonsteroid
antiinflammatori
agent
ibuprofen
antipyret
pain
reliev
acetaminophen
may
use
lessen
symptom
acut
phase
acut
bronchiti
eg
fever
muscl
ach
gonzal
sand
case
acut
bronchiti
caus
influenza
amantadin
rimantadin
may
effect
given
within
hour
onset
symptom
gonzal
sand
drug
block
proton
channel
requir
dissolut
viral
ribonucleoprotein
complex
earli
process
replic
zanamivir
oseltamivir
effect
influenza
b
like
amantadin
rimantadin
must
taken
within
first
hour
ill
drug
inhibit
neuraminidas
viral
surfac
glycoprotein
involv
releas
progeni
viru
spread
infect
cell
cell
larg
number
experiment
therapi
develop
treatment
chronic
obstruct
pulmonari
diseas
except
novel
antiinfect
agent
anticholinerg
bronchodil
tiotropium
experiment
therapi
develop
treatment
acut
infecti
bronchiti
mucolyt
agent
mucu
hypersecret
impair
mucociliari
clearanc
characterist
chronic
bronchiti
attempt
made
speed
transport
mucu
bronchiotrach
tree
wegner
oral
expector
guaifenesin
littl
benefit
chronic
obstruct
pulmonari
diseas
nacetylcystein
oral
administ
glutathion
precursor
reduc
sulfhydryl
bond
mucu
protein
shown
thin
sputum
without
produc
signific
improv
pulmonari
function
preliminari
studi
suggest
nacetylcystein
may
reduc
frequenc
acut
exacerb
action
may
relat
efficaci
antioxid
heliox
heliox
mixtur
helium
oxygen
chang
pulmonari
airflow
turbul
laminar
shown
decreas
work
breath
sever
stabl
chronic
obstruct
pulmonari
diseas
may
potenti
use
treatment
acut
exacerb
chronic
bronchiti
chitkara
sarina
rodrigo
et
al
cyclic
ampspecif
phosphodiesteras
predomin
proinflammatori
immun
cell
cilomilast
new
oral
activ
select
inhibitor
initi
studi
cilomilast
reveal
signific
function
improv
chronic
obstruct
pulmonari
diseas
copd
minim
side
effect
giembycz
signific
decreas
number
inflammatori
cell
characterist
copd
without
alter
sputum
valu
gambl
et
al
tiotropium
inhal
anticholinerg
avail
europ
pend
fda
approv
unit
state
barn
exhibit
slow
dissoci
muscarin
receptor
muscarin
receptor
allow
provid
oncedaili
dose
greater
degre
stabil
lung
function
ipratropium
tiotropium
may
use
acut
chronic
bronchiti
leukotrien
mediat
neutrophil
inflamm
elev
sputum
person
chronic
bronchiti
sever
antagonist
receptor
clinic
develop
may
use
treatment
chronic
bronchiti
kilfeath
number
agent
act
cytokin
pathway
mediat
symptom
chronic
obstruct
lung
diseas
copd
investig
barn
reid
sallenav
antiinflammatori
cytokin
decreas
cop
clinic
trial
variou
inflammatori
disord
underway
may
hold
promis
chronic
bronchiti
well
neutrophilattract
cytokin
elev
sputum
person
cop
inhibitor
antagonist
receptor
develop
may
use
treatment
chronic
bronchiti
tumor
necrosi
factoralpha
tnfalpha
proinflammatori
cytokin
activ
variou
immun
cell
stimul
product
inflammatori
cytokin
mediat
level
elev
sputum
individu
cop
monoclon
antibodi
direct
tnfalpha
infliximab
recombin
solubl
tnfalpha
receptor
etanercept
effect
rheumatoid
arthriti
inflammatori
disord
may
use
manag
chronic
bronchiti
inhibitor
oxid
stress
nacetylcystein
cystein
donor
enhanc
product
antioxid
glutathion
decreas
oxid
stress
shown
reduc
frequenc
acut
exacerb
chronic
bronchiti
wegner
addit
antioxid
stabl
glutathion
compound
superoxid
dismutas
analog
clinic
develop
induc
nitric
oxid
synthetas
ino
respons
product
peroxynitrit
potent
oxid
speci
releas
inflamm
inhibitor
ino
develop
may
use
treatment
chronic
bronchiti
inhibitor
proteas
eg
elastas
releas
neutrophil
inflammatori
process
chronic
obstruct
pulmonari
diseas
develop
barn
compound
may
slow
progress
emphysema
accompani
certain
case
chronic
bronchiti
mitogenactiv
protein
map
kinas
involv
express
inflammatori
cytokin
proteas
involv
chronic
bronchiti
inhibitor
map
kinas
develop
may
use
treat
chronic
bronchiti
barn
inhibitor
kinasegamma
enzym
involv
neutrophil
activ
may
also
valu
inhibitor
nfkappab
signal
pathway
develop
may
test
treatment
chronic
bronchiti
model
acut
infecti
bronchiti
involv
anim
infect
caus
viral
agent
exampl
mice
ferret
chicken
infect
influenza
virus
commonli
use
search
new
antiinfluenza
drug
sidwel
smee
number
anim
model
commonli
employ
studi
chronic
bronchiti
nikula
green
hamster
dog
rat
expos
sulfur
dioxid
week
develop
clinic
histolog
sign
chronic
bronchiti
mice
rat
guinea
pig
dog
sheep
monkey
use
studi
role
cigarett
smoke
develop
chronic
bronchiti
emphysema
rat
mice
hamster
guinea
pig
expos
organ
dust
eg
cotton
dust
bacteri
endotoxin
use
model
occup
exposur
result
chronic
bronchiti
form
lung
inflamm
exposur
substanc
nickel
nitric
acid
also
examin
lazaru
sj
expert
strive
better
defin
pathophysiolog
cop
articl
examin
new
direct
studi
copd
patholog
http
wwwmedscapecom
croxton
tl
weinmann
gg
senior
rm
wise
ra
crapo
j
buist
clinic
research
chronic
obstruct
pulmonari
diseas
need
opportun
http
wwwnhlbinihgovmeetingsworkshopscopdclinicalhtm
unit
state
depart
health
human
servic
cdc
nch
nation
health
interview
survey
web
site
contain
data
preval
copd
symptom
unit
state
impact
activ
daili
life
also
epidemiolog
inform
number
medic
condit
http
wwwcdc
govnchsnhishtm
bandi
va
apicella
mason
e
murphi
tf
siddiqi
atmar
rl
greenberg
sg
nontyp
haemophilu
influenza
lower
respiratori
tract
patient
chronic
bronchiti
j
respir
crit
care
med
